You’re cruising through a Q-bank and you hit a question on immune tolerance—and suddenly every answer choice sounds kind of right. That’s not accidental: tolerance is a “web concept” in immunology where central vs peripheral, T vs B cells, and autoimmunity vs transplant all overlap. The quickest way to stop losing points is to learn how to prove the correct answer and disprove every distractor.
Tag: Immunology > Transplant & Autoimmune
The Clinical Vignette (Q-bank style)
A 28-year-old woman with a history of autoimmune thyroid disease receives a kidney transplant from a deceased donor. She is started on tacrolimus, mycophenolate mofetil, and prednisone. Six months later, she is clinically well. Labs show stable creatinine. A research team evaluates her immune profile and finds that recipient T cells specific for donor HLA are present but demonstrate poor proliferative response to donor antigen stimulation in vitro. The team also notes increased expression of CTLA-4 and expansion of CD4+ FOXP3+ T cells.
Which mechanism best explains this patient’s reduced T-cell response to donor antigens?
A. Deletion of autoreactive T cells in the thymic medulla via AIRE
B. Induction of T-cell anergy due to absent costimulation (B7–CD28 signaling)
C. Class switching of donor-specific B cells to IgG4
D. Hypermutation-driven affinity maturation in germinal centers
E. Complement-mediated lysis of donor antigen-presenting cells
The Correct Answer: B. Induction of T-cell anergy due to absent costimulation
This vignette points to peripheral tolerance, not central tolerance. The key clue is that donor-specific T cells still exist but are functionally “turned off” (poor proliferation). Add in the CTLA-4 mention and you’re being steered toward loss of costimulation.
Why anergy fits best
Naive T cells require two signals to activate:
- Signal 1: TCR recognizes peptide–MHC on APC
- Signal 2 (costimulation): B7 (CD80/86) on APC binds CD28 on T cell
If Signal 1 occurs without Signal 2, the T cell becomes anergic (functionally unresponsive), which is a major mechanism of peripheral tolerance.
How CTLA-4 locks this in
- CTLA-4 is an inhibitory receptor on T cells (especially Tregs) that binds B7 with higher affinity than CD28.
- When CTLA-4 engages B7, it reduces IL-2 production and T-cell proliferation.
High-yield tie-in:
- Abatacept / Belatacept are CTLA-4–Ig fusion proteins that bind B7 and block costimulation, used clinically to prevent transplant rejection.
“Why Every Answer Choice Matters”: Systematic Distractor Breakdown
A. Deletion of autoreactive T cells in the thymic medulla via AIRE (Central tolerance)
This is real—but it doesn’t match the scenario.
What AIRE actually does:
- Expresses peripheral tissue antigens in the thymus
- Promotes negative selection (apoptosis) of self-reactive T cells in the medulla
Why it’s wrong here:
- AIRE is about tolerance to self, not donor antigens.
- Central tolerance happens during T-cell development, not “6 months after transplant.”
- The stem of the question tells you donor-reactive T cells are present, suggesting they were not deleted.
Step 1 association: AIRE mutation → APECED (chronic mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency).
C. Class switching of donor-specific B cells to IgG4
Class switching is important in humoral immunity, allergy, and some chronic antigen exposure settings—but this doesn’t explain poor T-cell proliferation to donor HLA.
High-yield facts:
- Class switching requires T-cell help (CD40–CD40L + cytokines).
- IgG4 is often associated with chronic antigen exposure and certain fibroinflammatory diseases (IgG4-related disease), not classic transplant tolerance.
Why it’s wrong here:
- The vignette’s key data are T-cell functional unresponsiveness plus CTLA-4/Treg signals.
- Donor-specific antibody biology matters in transplant (antibody-mediated rejection), but that’s not what’s being tested.
D. Hypermutation-driven affinity maturation in germinal centers
This is a frequent distractor because it sounds “immunology-smart,” but it’s the wrong compartment and wrong mechanism.
What it really is:
- Somatic hypermutation in germinal centers (AID enzyme)
- Produces higher-affinity antibodies
- Happens in B cells, not T cells
Why it’s wrong here:
- Affinity maturation increases the effectiveness of antibodies; it does not cause T-cell anergy.
- The clinical stem is pointing you to T-cell tolerance, not improved antibody binding.
Step 1 reminder: AID deficiency → Hyper-IgM syndrome type 2 (no class switching, no affinity maturation).
E. Complement-mediated lysis of donor antigen-presenting cells
Complement is a killer pathway, but it’s not a physiologic tolerance mechanism—if anything, complement activation tends to amplify inflammation and graft injury.
High-yield transplant tie-in:
- Hyperacute rejection: preformed IgG against donor ABO/HLA → complement activation → thrombosis/necrosis (minutes to hours)
- Antibody-mediated (humoral) rejection: C4d deposition, endothelial injury
Why it’s wrong here:
- She’s stable at 6 months with signs of immune quiescence, not acute inflammatory destruction.
- Complement lysis of APCs isn’t the classic explanation for donor-specific T-cell hyporesponsiveness.
The Bigger Concept: Central vs Peripheral Tolerance (Rapid Table)
| Feature | Central tolerance | Peripheral tolerance |
|---|---|---|
| Where | Thymus (T), bone marrow (B) | Peripheral tissues/lymph nodes |
| Target | Self-reactive lymphocytes | Self-reactive or persistently stimulated lymphocytes |
| Main mechanisms | Negative selection (apoptosis), receptor editing (B cells) | Anergy, deletion, Treg suppression |
| Classic buzzwords | AIRE, negative selection | CTLA-4, PD-1, FOXP3 Tregs, costimulation |
How This Shows Up on USMLE (High-Yield Patterns)
Pattern 1: “Signal 1 without Signal 2”
If they describe antigen recognition but absent costimulation → Anergy
- Missing B7 on APC (immature/resting APC)
- Blocking B7–CD28 (e.g., belatacept)
Pattern 2: “FOXP3+ Tregs increased”
Think immune suppression/tolerance, via:
- IL-10, TGF-β secretion
- CTLA-4–mediated inhibition of costimulation
- Suppression of effector T-cell activation
Step 1 association: FOXP3 mutation → IPEX (immune dysregulation, polyendocrinopathy, enteropathy; eczema, diabetes, diarrhea).
Pattern 3: PD-1 / checkpoint inhibitors
If they mention PD-1/PD-L1 or CTLA-4 blockade:
- Blocking checkpoints (ipilimumab, nivolumab, pembrolizumab) → increased T-cell activity → autoimmune-like toxicities
- Not tolerance; it’s the opposite.
Quick Takeaways (What to Remember Under Time Pressure)
- Anergy = Signal 1 without Signal 2 (B7–CD28 absent or blocked).
- CTLA-4 is inhibitory and competes with CD28 for B7 → decreased T-cell activation.
- AIRE = central tolerance (thymic negative selection to self-antigens).
- Germinal center processes (class switch, somatic hypermutation) are B-cell antibody optimization, not T-cell tolerance.
- Complement activation is usually a clue for antibody-mediated transplant injury, not tolerance.